Previous study has shown that AZD8931 inhibits human tumor xenograft growth with different sensitivities to agents targeting either EGFR or HER2 in a variety of models including one human breast cancer cell line BT-474, which expresses ER/PgR, high levels of HER2, and moderate levels of EGFR[16]. Here, ERBB2 is linked to breast carcinoma.